Neuronetics Board Agrees Valuation Undervalues NeuroStar Platform, Seeks Engagement
Neuronetics’ Board reviewed a public letter from Pointillist Family Office highlighting that current market valuation fails to reflect the strength of its NeuroStar® Advanced Therapy platform. The Board confirmed its commitment to maximizing shareholder value and said it is open to constructive shareholder engagement while executing its long-term strategic priorities.
1. Activist Letter Highlights Undervaluation
Jorey Chernett of Pointillist Family Office addressed the Board on April 6, citing a gap between market valuation and the strength of Neuronetics’ NeuroStar Advanced Therapy business. The letter urged the Board to pursue initiatives that unlock shareholder value.
2. Board Affirms Commitment and Engagement
The Board reviewed the letter and stated it will act in shareholders’ best interests, agreeing that current valuation does not fully reflect business strength. Management affirmed its openness to constructive dialogue as it executes strategic priorities.
3. Company Focus and Growth Drivers
Neuronetics markets NeuroStar Advanced Therapy and operates Greenbrook TMS treatment centers delivering the leading transcranial magnetic stimulation system for major depressive disorder. The company aims to expand coverage and treatment access to drive revenue and long-term value.